This play is absolutely a bottom fishing expedition. However, TYME is above the conversion line and on Friday made a decisive close over the base line after a long downtrend, and on a huge volume spike. The cloud looms overhead as resistance, and there’s no telling what will happen then. Entry will be above Friday’s high, with a protective stop below the low.
So based on the pattern, a spike could happen in the near future. I see that the possible support area is $2.00-$2.05. Will momentum continue, or will is dip back down to support? I would prefer that it dips back down so I can get in at the support area, but if not I am will get in on a red day. Either way, the pattern is holding true. I am just looking for a good...
So I have been watching this one as well. Based on the chart, it consolidates, then rally, consolidates, then rally. I has already consolidated, but can it rally again?
Here we have a Double Buy alert from the DBT MoMo leading to a 42% move on TYME in just two trading days. Once the double buy was alerted it consolidated for one trading day finding support. After the news announcement came in so did the volume. With the volume surge we saw an easy push up to $3.
Tyme Technologies, Inc. is a clinical-stage biotechnology company. The Company is focused on developing cancer therapeutics that is intended to be broadly effective across tumor types and have low toxicity profiles. The Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. The Company’s lead clinical program, SM-88, is a first-in-class combination therapy in Phase II development for prostate cancer, and it is preparing to initiate an additional Phase II clinical trial for pancreatic cancer. The Company provides a novel compound for physicians to use in a treatment regimen for patients fighting six major cancers including breast, lung, prostate, gastric, esophageal and pancreatic cancers.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
TYME
